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A b s t r a c t
Introduction: A large, randomised trial (IABP-SHOCK II) confirmed no benefit of intra-aortic balloon pump (IABP) on clinical 
outcomes of patients with ST-segment elevation myocardial infarction (STEMI) complicated by cardiogenic shock. However, the 
‘sickest’ patients are often excluded from randomised clinical trials, so it is difficult to generalise expected outcomes from random-
ized clinical trials to the real life setting.
Aim: We sought to evaluate the impact of IABP on 1-year mortality of unselected patients with STEMI presenting in cardiogenic shock.
Material and methods: Data were gathered for 1,650 consecutive patients with STEMI transferred for primary angioplasty from 
hospital networks in 7 countries in Europe from November 2005 to January 2007 (the EUROTRANSFER registry population). Of them, 
51 patients with cardiogenic shock on admission were identified and stratified based on the use of IABP. Outcome results were 
adjusted for age and sex, to control possible selection bias.
Results: At the discretion of the operators, IABP was applied in 30 patients (58.8%, IABP group). The remaining 21 patients were 
treated without IABP (no-IABP group). The use of IABP was more frequent among males, younger patients, and patients with STEMI of 
the anterior wall. There was no difference in 30-day mortality in patients with and without IABP (no-IABP vs. IABP: 38.1% vs. 33.3%; ad-
justed OR 1.79 (95% CI 0.43–7.52); p = 0.43). Similarly, IABP had no impact on 1-year mortality (42.9% vs. 33.3%; adjusted OR 1.27 (95% 
CI 0.32–5.09); p = 0.74). One-year mortality was comparable among patients who survived hospitalisation (14.3% vs. 13%; p = 0.64).
Conclusions: We observed no benefit of IABP on short – and long-term mortality of unselected patients with STEMI complicated 
by cardiogenic shock.
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Introduction
Cardiogenic shock is the leading cause of death 
among patients hospitalised with ST-segment elevation 
myocardial infarction (STEMI) [1–7]. Early revascularisa-
tion, with both percutaneous coronary intervention (PCI) 
and coronary artery bypass grafting (CABG) leads to 
a  survival benefit in these patients [8, 9]. According to 
current guidelines, additional intra-aortic balloon pump 
(IABP) support may be considered in patients with STEMI 
and cardiogenic shock [10, 11].
Intra-aortic balloon pump improves myocardial and 
peripheral perfusion, and reduces afterload, as well as 
myocardial oxygen consumption [6, 12–14]. These effects 
are believed to improve myocardial recovery during isch-
aemia and reperfusion. On the other hand, the benefit 
of IABP in patients with STEMI and cardiogenic shock 
undergoing primary PCI were not proven by a meta-anal-
ysis of cohort studies [15]. In addition, the impact of IABP 
on long-term survival of patients with STEMI and car-
diogenic shock remains unclear because the majority of 
previous studies have focused on short-term outcomes 
[15–19]. Recently, a large, randomised IABP-SHOCK II trial 
confirmed no benefit of IABP on short – and long-term 
outcomes of patients with STEMI complicated by cardio-
genic shock [20, 21]. However, the ‘sickest’ patients are 
often excluded from randomised clinical trials, so it is dif-
ficult to generalise expected outcomes from randomized 
clinical trials to the real life setting.
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Aim
We sought to evaluate the impact of IABP on 1-year 
mortality in an unselected cohort of patients with STEMI 
complicated by cardiogenic shock, based on data from 
the EUROTRANSFER (European Registry on Patients with 
ST-Elevation MI Transferred for Mechanical Reperfusion 
with a  Special Focus on Upstream Use of Abciximab) 
Registry [22–24]. 
Material and methods
The EUROTRANSFER Registry (ClinicalTrials.gov num-
ber NCT00378391) design and main results have been 
published elsewhere [22–24]. In this registry, data on 
1,650 patients with STEMI in 15 primary PCI networks 
from 7 European countries between November 2005 and 
January 2007 were collected. For the present analysis, the 
data of 51 (3.1%) patients with STEMI and cardiogenic 
shock on admission (systolic blood pressure < 90 mm Hg, 
heart rate > 100 bpm, and clinical signs of organ hypoper-
fusion) were assessed. Patients were stratified by use of 
IABP during index hospital stay: no-IABP vs. IABP. The 
treatment strategies, including the use of IABP and the 
timing of insertion, were at the discretion of operators. 
The study protocol and execution complied with the Dec-
laration of Helsinki and was approved by the Institutional 
Review Board.
The primary endpoint was 1-year all-cause mortality. 
Secondary endpoints were: 30-day all-cause mortality, 
nonfatal reinfarction, urgent revascularisation (PCI or 
CABG), major bleeding requiring transfusion, and punc-
ture site haematoma [22–24]. Thrombolysis In Myocardi-
al infarction (TIMI) flow in the infarct-related artery be-
fore and after PCI, ST-segment resolution after PCI, and 
the rate of angiographic complications of PCI (no-reflow, 
distal embolisation) were assessed at the investigators’ 
discretion. 
Statistical analysis
Continuous variables were presented as medians 
(interquartile ranges). Categorical variables were ex-
pressed as numbers (percentages). Differences between 
groups (no-IABP vs. IABP) were tested using the χ2 test 
and Fisher’s exact test for dichotomous variables and the 
Mann-Whitney U-test for continuous variables. The effect 
of IABP vs. no-IABP on clinical outcomes was presented as 
odds ratios (OR) and 95% confidence intervals (CI). To ad-
just for possible selection bias, differences in clinical out-
comes were adjusted for age and sex using logistic regres-
sion. Results were presented as adjusted OR with 95% CI. 
The survival curves were estimated by the Kaplan-Meier 
method and compared using log-rank test. All tests were 
2-tailed, and a p value of < 0.05 was considered statistical-
ly significant. All statistical analysis was performed using 
SPSS software, version 15.0 (SPSS Inc., Chicago, Illinois).
Results
In total, 1,650 patients with STEMI from 15 primary 
PCI centres between November 2005 and January 2007 
were included in the EUROTRANSFER Registry. Of these, 
51 (3.1%) patients were in cardiogenic shock on admis-
sion. At the discretion of the operators, IABP was used 
in 30 patients (58.8%, IABP group). The remaining 21 pa-
tients were treated without IABP (41.2%, no-IABP group). 
As shown in Tables I and II, the use of IABP was more 
frequent among males, younger patients, and patients 
with the left anterior descending artery as the infarct-re-
lated artery.
Impact of intra-aortic balloon pump on clinical
outcomes
Immediate PCI was performed in 30 (100%) patients 
from the IABP group, and in 18 (85.7%) patients from the 
no-IABP group (p = 0.06). Two patients from the no-IABP 
group were transferred for urgent CABG. The rate of stent 
implantation and thrombus aspiration was comparable 
between the two groups (Table II). Despite no difference 
in the rate of TIMI grade 3 flow after PCI, the rate of 
ST-segment resolution > 50% 60 min after PCI was nu-
merically higher in patients from the no-IABP group (no-
IABP vs. IABP: 47.6% vs. 26.7%; p = 0.15).
The overall 30-day and 1-year mortality for patients 
in cardiogenic shock was 35.3% and 37.3%, respectively. 
Even after adjustment for age and sex, there was no dif-
ference in short – and long-term mortality between pa-
tients treated with and without IABP (Table III, Figure 1). 
Similarly, no difference in 1-year mortality was observed 
when the infarct-related artery (left anterior descending 
artery (LAD) vs. no-LAD) and diabetes mellitus were add-
ed to the adjustment model – adjusted OR (95% CI) – 1.48 
(0.30–7.33). There was also no difference in 1-year mortal-
ity between groups of patients who survived hospitalisa-
tion (no-IABP vs. IABP: 14.3% vs. 13.0%; p = 0.64). The rate 
of bleedings was comparable between groups (Table III).
Discussion
The main finding of the present study is that among 
patients with STEMI complicated by cardiogenic shock, 
treatment with IABP had no impact on short – and long-
term survival. On the other hand, despite the higher risk 
attributed to patients from the IABP group, the long-term 
outcomes were comparable to those observed in low-
er-risk patients treated without IABP. This may suggest 
a beneficial effect of IABP in a selected group of patients.
The observed rate of cardiogenic shock on admission 
was comparable to that previously reported for patients 
with STEMI [3–5, 7]. Also, short – and long-term mortal-
ity rates were similar to those reported for patients un-
dergoing early revascularisation in the setting of STEMI 
complicated by cardiogenic shock [4, 5, 8, 9, 17, 18, 25].
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Table I. Baseline clinical characteristics of patients with and without intra-aortic balloon pump
Variable Intra-aortic balloon pump Value of p
No
(n = 21)
n (%)/median (range)
Yes
(n = 30)
n (%)/median (range)
Age [years] 72 (62–81) 64.5 (52–74) 0.018
Age ≥ 65 years 14 (66.7) 15 (50.0) 0.24
Men 8 (38.1) 25 (83.8) 0.001
Body mass index [kg/m2] 26.9 (23.2–28.5) 27.4 (24.7–29.3) 0.24
Diabetes mellitus 1 (4.8) 8 (26.7) 0.06
Previous myocardial infarction 4 (19.0) 8 (26.7) 0.74
Previous heart failure symptoms 1 (4.8) 2 (6.7) 0.99
Previous percutaneous coronary intervention 1 (4.8) 2 (6.7) 0.99
Previous coronary artery bypass grafting 0 (0.0) 0 (0.0) –
Current smoker 5 (23.8) 8 (26.7) 0.82
Peripheral arterial disease 1 (4.8) 0 (0.0) 0.41
Previous stroke 2 (9.5) 0 (0.0) 0.17
Chronic kidney disease 1 (4.8) 0 (0.0) 0.41
Time from symptoms onset to diagnosis [min] 92 (53–133) 80 (45–293) 0.72
Aspirin before cathlab 15 (71.4) 26 (86.7) 0.28
Clopidogrel before cathlab 2 (9.5) 7 (23.3) 0.28
Unfractionated heparin before cathlab 13 (61.9) 16 (53.3) 0.54
Abciximab before cathlab 5 (23.8) 14 (46.7) 0.14
Values are presented as numbers (percentages) or medians (inter-quartile range)
Table II. Invasive treatment details of patients with and without intra-aortic balloon pump
Variable Intra-aortic balloon pump Value of p
No
(n = 21)
n (%)/median (range)
Yes
(n = 30)
n (%)/median (range)
Femoral access 20 (95.2) 27 (90.0) 0.63
LAD as infarct-related artery 8 (38.1) 20 (66.7) 0.044
Multi-vessel disease 16 (76.2) 20 (69.0) 0.57
TIMI grade 2 to 3 flow before PCI 3 (14.3) 3 (10.0) 0.68
Time from symptoms onset to PCI [min] 226 (139–352) 220 (136–460) 0.87
Immediate PCI 18 (85.7) 30 (100) 0.06
Number of stents implanted:
1 11 (68.8) 17 (65.4) 0.69
2 3 (18.8) 7 (26.9)
3 2 (12.5) 1 (3.8)
≥ 4 0 (0.0) 1 (3.8)
Thrombus aspiration 1 (5.6) 5 (16.7) 0.39
Drug-eluting stent 7 (38.9) 8 (26.7) 0.52
Non-infarct-related artery PCI 2 (11.1) 4 (13.3) 0.99
TIMI grade 3 flow after PCI 16 (88.9) 24 (80.0) 0.81
Angiographic complications of PCI:
No-reflow 0 (0.0) 2 (6.7) 0.52
Distal embolisation 0 (0.0) 2 (6.7) 0.52
Values are presented as numbers (percentages) or medians (inter-quartile range). LAD – the left anterior descending artery, PCI – percutaneous coronary intervention, 
TIMI – Thrombolysis In Myocardial Infarction
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In our study, IABP was used in up to 60% of patients 
with STEMI and cardiogenic shock on admission. Con-
versely, it was used in 25% of patients with cardiogenic 
shock included between May 2005 and April 2008 in the 
Euro Heart Survey on PCI [18]. A more recent report from 
the ALKK-PCI registry confirms significant differences 
in the use of IABP between various German hospitals, 
ranging from 0 to 70%, with an overall rate of 25.5% [17]. 
The recent decrease in the use of IABP in Europe [17, 18, 
26] is probably related to the results of a meta-analysis 
of cohort studies from Sjauw et al. published on 2009 
[15]. In this meta-analysis no mortality benefit of IABP 
in patients with STEMI complicated by cardiogenic shock 
treated with primary PCI was confirmed. Importantly, 
the use of IABP was associated with an increase in ma-
jor bleeding complications and stroke [15]. In the largest 
study to date on IABP support in patients with STEMI 
complicated with cardiogenic shock (the IABP-SHOCK II 
trial), no reduction of 30-day and 1-year mortality was 
observed in patients treated with IABP, as compared to 
patients without IABP [20, 21]. Also, there was no dif-
ference in other clinical endpoints, including stroke. In 
the updated meta-analysis from Romeo et al. (13 ob-
servational studies, 4 randomised clinical trials) a  sig-
nificant increase of in-hospital mortality was observed 
in patients with cardiogenic shock undergoing primary 
PCI supported by IABP [19]. Interestingly, the benefit of 
IABP was limited to patients with STEMI and cardiogenic 
shock treated with thrombolytic therapy [19].
Using the data from the EUROTRANSFER registry, we 
observed no impact of IABP on short-term mortality of 
patients with STEMI and cardiogenic shock on admis-
sion. Our study may also suggest that IABP support in 
patients with STEMI and cardiogenic shock on admission 
did not improve long-term clinical outcomes compared 
to no IABP. Importantly, observed 1-year mortality rates 
for patients who survived hospitalisation were low, and 
comparable between groups. This finding is in line with 
the results of the study from Singh et al. [27] In this study, 
the long-term mortality of patients with STEMI and car-
diogenic shock, and who survived hospitalisation, was 
low and similar to that reported for patients with STEMI 
without cardiogenic shock [28, 29].
Our study has a number of potential limitations. This 
is a non-randomised study with the potential of selection 
bias. The two groups were not balanced for important 
factors affecting long-term outcomes in patients with 
STEMI (gender, age, infarct location, and diabetes mel-
litus). Due to the very small sample size, the study was 
underpowered for the assessment of clinical endpoints. 
We were unable to calculate propensity scores or to con-
trol patient-, operator-, and centre-related factors influ-
encing the association between IABP use and patient 
outcomes. The analysed 1-year outcomes were limited to 
Table III. Clinical outcomes of patients with and without intra-aortic balloon pump
Variable Intra-aortic balloon pump OR (95% CI) Value 
of p
Adjusted OR 
(95% CI)
Value 
of pNo
(n = 21)
n (%)
Yes
(n = 30)
n (%)
30-day:
Death 8 (38.1) 10 (33.3) 0.81 (0.25–2.60) 0.73 1.79 (0.43–7.52) 0.43
Death + nonfatal reinfarction 9 (42.9) 11 (36.7) 0.77 (0.25–2.41) 0.66 1.45 (0.36–5.78) 0.60
Death + nonfatal reinfarction + 
urgent revascularisation
9 (42.9) 14 (46.7) 1.17 (0.38–3.59) 0.79 2.53 (0.61–10.45) 0.20
Major bleeding requiring 
transfusion
1 (4.8) 1 (3.2) 0.69 (0.04–11.68) 0.99 1.36 (0.05–38.88) 0.86
Puncture site haematoma 2 (9.5) 2 (6.7) 0.68 (0.09–5.24) 0.99 1.08 (0.11–11.13) 0.95
1-year:
Death 9 (42.9) 10 (33.3) 0.67 (0.21–2.11) 0.49 1.27 (0.32–5.09) 0.74
Values are presented as numbers (percentages) and as odds ratios (OR) with 95% confidence intervals (CI), unadjusted and adjusted for age and sex
Figure 1. Kaplan-Meier survival curves for patients 
treated with (solid line) and without (dotted line) 
intra-aortic balloon pump
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mortality only, and important data on heart failure symp-
toms or neurological outcomes were not available. Also, 
we were unable to assess the impact of IABP timing on 
clinical outcomes because no data on the timing of IABP 
insertion (before, during, or after angiography/PCI) were 
available. The study by Abdel-Wahab et al. suggests that 
patients with cardiogenic shock (either on admission or 
during hospitalisation) undergoing primary PCI assisted 
by IABP have a more favourable in-hospital outcome and 
lower in-hospital mortality than patients who receive 
IABP after PCI [30]. Conversely, no association between 
the time of IABP insertion (before PCI vs. after PCI) and 
30-day mortality was reported for patients with cardio-
genic shock on admission [31]. In addition, no data on the 
use of antithrombotic and antiplatelet drugs, as well as 
inotropes/vasopressors during index hospital stay, were 
collected in the EUROTRANSFER registry, and no data on 
important admission laboratory predictors of mortality in 
cardiogenic shock, such as glucose, lactate, and creati-
nine clearance, were available.
Conclusions
We observed no benefit of IABP on short – and long-
term mortality of unselected patients with STEMI compli-
cated by cardiogenic shock.
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